Specifically, three IL-1 blockers have shown clinical efficacy in BD patients, the IL-1 receptor antagonist anakinra, as well as canakinumab and gevokizumab, targeting the IL-1 molecule directly, which have proved to be effective for all BD manifestations, especially for the most severe ocular involvement (110). Here, IL1B is linked to Behcet disease.